Advertisement
Australia markets closed
  • ALL ORDS

    8,070.10
    -9.10 (-0.11%)
     
  • ASX 200

    7,822.30
    -9.50 (-0.12%)
     
  • AUD/USD

    0.6743
    +0.0014 (+0.21%)
     
  • OIL

    83.81
    -0.07 (-0.08%)
     
  • GOLD

    2,397.90
    +28.50 (+1.20%)
     
  • Bitcoin AUD

    84,167.91
    -2,058.85 (-2.39%)
     
  • CMC Crypto 200

    1,177.36
    -31.33 (-2.60%)
     
  • AUD/EUR

    0.6226
    +0.0006 (+0.09%)
     
  • AUD/NZD

    1.0983
    -0.0009 (-0.08%)
     
  • NZX 50

    11,794.81
    +48.15 (+0.41%)
     
  • NASDAQ

    20,390.20
    +203.56 (+1.01%)
     
  • FTSE

    8,203.93
    -37.33 (-0.45%)
     
  • Dow Jones

    39,295.31
    -12.69 (-0.03%)
     
  • DAX

    18,475.45
    +24.97 (+0.14%)
     
  • Hang Seng

    17,799.61
    -228.67 (-1.27%)
     
  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.